Nangibotide
A peptide inhibitor of TREM-1-pathway amplification studied in septic shock.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Investigational
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A peptide inhibitor of TREM-1-pathway amplification studied in septic shock.
Investigational; not FDA-approved for the uses discussed.
A subgroup analysis cannot substitute for a successful primary trial outcome or establish a survival benefit.
Why It's Being Studied
- Septic shock
- TREM-1 signalling
Mechanism of Action
It is intended to attenuate amplified innate immune signalling rather than eliminate an infection directly.
It is intended to attenuate amplified innate immune signalling rather than eliminate an infection directly. A subgroup analysis cannot substitute for a successful primary trial outcome or establish a survival benefit.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Septic shock
- TREM-1 signalling
- Intravenous clinical research
Evidence Summary
Phase 2b ASTONISH did not establish benefit in its prespecified primary analysis; biomarker-selected signals require confirmation.
Higher tiers carry more weight. Filled tiers have evidence for Nangibotide; tap to read it.
- Phase 2b ASTONISH did not establish benefit in its prespecified primary analysis; biomarker-selected signals require confirmation.
1 cited sources.
- Phase 2 trial1
Human clinical evidence
- Phase 2b ASTONISH did not establish benefit in its prespecified primary analysis; biomarker-selected signals require confirmation.
Reported Adverse Events in Research
- Critically ill populations and incomplete long-term evidence limit safety interpretation.
Limitations of Current Evidence
- A subgroup analysis cannot substitute for a successful primary trial outcome or establish a survival benefit.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Nangibotide | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Phase 2 trial
Nangibotide — phase 2 trial